Avacta Group widens half-year losses as sales slow

Animal and human healthcare company Avacta Group widened its half-year losses as revenues slowed during the introduction of new Optim analytical devices.

Animal and human healthcare company Avacta Group widened its half-year losses as revenues slowed during the introduction of new Optim analytical devices.

The provider of analytical and diagnostic technologies to the pharmaceutical and animal healthcare sectors, posted an operating loss of £0.97m in the six months to the end of January, up from £0.52m the previous year.

Revenues dropped to £1.15m from £1.72m during the transition from Optim1 to Optim2, an analytical instrument designed to probe multiple protein stability-indicating parameters.

The company has received orders for 10 units since launching the product on February 1st.

During the period, the company invested in training its sales team at ForteBio, the the newly acquired subsidiary of partner Pall Corporation. ForteBio is the key distributor for the US market of the Optim product.

"Revenues fell because Optim sales slowed as we introduced Optim2 and trained up the sales team at ForteBiom," Chief Executive Officer Alastair Smith told Digital Look and Sharecast.

He said it was a transformational period for the company which resulted in a short-term slowdown that will drive performance in the long run.

The company expects to launch its new Affimer reagents next year as development remains in line with management's expectations.

"The antibody replacement technology presents a lot of growth opportunities," he said.

"Over the next half we anticipate further progress across all divisions."

RD

Recommended

The MoneyWeek Podcast: picking stocks is fun, but you need to do your homework
Investment strategy

The MoneyWeek Podcast: picking stocks is fun, but you need to do your homework

John Stepek talks to Steve Clapham, investor, analyst and author of The Smart Money Method, about the dangers in picking individual stocks and why you…
8 Apr 2021
BP looks set to return more money to shareholders as it beats expectations
Energy stocks

BP looks set to return more money to shareholders as it beats expectations

Oil major BP is to embark on a share buyback programme after significantly reducing its debts. Saloni Sardana looks at what it means for your portfoli…
6 Apr 2021
Deliveroo has hit the market – but it’s not getting the warmest welcome
UK stockmarkets

Deliveroo has hit the market – but it’s not getting the warmest welcome

Food delivery company Deliveroo made its debut on the stockmarket this morning. But with the share price sliding by 30% straight away, it’s not made t…
31 Mar 2021
Three stocks to buy now that will come back stronger after Covid-19
Share tips

Three stocks to buy now that will come back stronger after Covid-19

Professional investor Ed Wielechowski of Odyssean Capital, chooses three compelling stocks that should thrive in a post-pandemic world.
29 Mar 2021

Most Popular

The bitcoin bubble will burst: here’s how to play it
Bitcoin

The bitcoin bubble will burst: here’s how to play it

The cryptocurrency’s price has soared far beyond its fundamentals, says Matthew Partridge. Here, he looks at how to short bitcoin.
12 Apr 2021
What does the Coinbase listing mean for bitcoin and other cryptocurrencies?
Bitcoin

What does the Coinbase listing mean for bitcoin and other cryptocurrencies?

As the bitcoin price hit new highs, the world's biggest cryptocurrency exchange, Coinbase, listed on the stockmarket. John Stepek looks at what that m…
15 Apr 2021
Properties for sale for around £400,000
Houses for sale

Properties for sale for around £400,000

From a converted church in Banffshire with views towards the Cairngorms National Park, to a period property in the Georgian market town of Beverley, e…
2 Apr 2021